Impact of the Restriction of Sources of Gluten in Fibromyalgia Patients
Primary Purpose
Fibromyalgia
Status
Completed
Phase
Not Applicable
Locations
Brazil
Study Type
Interventional
Intervention
Gluten
Rice protein
Sponsored by
About this trial
This is an interventional basic science trial for Fibromyalgia focused on measuring Fibromyalgia; non-celiac gluten sensitivity
Eligibility Criteria
Inclusion Criteria:
• Women between 18 and 65 years of age with prior clinical diagnosis of FM, according to the American College of Rheumatology criteria of 2010
Exclusion Criteria:
- Subjects diagnosed with positive serology for celiac disease or allergy to wheat
- Subjects diagnosed with autoimmune diseases
- Subjects with diseases that are not part of the comorbidities associated with FM and t hat could influence the results of the study
- Pregnant or lactating women
Sites / Locations
- Laboratório de Aterosclerose e Bioquimica Nutricional
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Gluten
Rice protein
Arm Description
Capsules containing 8 g/day of gluten (6,3g of protein) were blindly administered for 7 days
Capsules containing 6,4 g/day of rice protein were blindly administered for 7 days
Outcomes
Primary Outcome Measures
Changes in fibromyalgia Symptoms by Salerno protocol
Self report of symptoms intensity in the last week. Each item is scored 0 (no symptom) to 10 (very intense symptom).
Secondary Outcome Measures
Changes in body weight
measured in weight in kg
Height
measured in meters
changes in BMI
in kg of body weight/square of height
Changes in IL-6 blood concentration
measure by ELISA in ug/mL
Changes in IL-10 blood concentration
measure by ELISA in ug/mL
Changes in IL-1beta blood concentration
measure by ELISA in ug/mL
changes in Food intake
measured in % of kcal
Full Information
NCT ID
NCT03129906
First Posted
April 19, 2017
Last Updated
April 21, 2017
Sponsor
Federal University of Minas Gerais
1. Study Identification
Unique Protocol Identification Number
NCT03129906
Brief Title
Impact of the Restriction of Sources of Gluten in Fibromyalgia Patients
Official Title
Impact of the Restriction of Sources of Gluten in Fibromyalgia Patients
Study Type
Interventional
2. Study Status
Record Verification Date
April 2017
Overall Recruitment Status
Completed
Study Start Date
September 25, 2015 (undefined)
Primary Completion Date
October 4, 2016 (Actual)
Study Completion Date
October 4, 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Federal University of Minas Gerais
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The aim of this study is to evaluate the impact of gluten-free diets on symptoms and inflammatory markers in individuals with previous diagnosis of fibromyalgia (FM), as well as to identify the presence of non-celiac gluten sensitivity (NCSG) in individuals with FM. Patients with FM diagnosis will be kept on a gluten-free diet for a 10 weeks. In the 7th week, they will receive placebo capsules for 7 days and after washout, capsules containing gluten for another 7 days. A questionnaire based on Salerno protocol will be applied to evaluate the presence of NCGS in the beginning, 8th week and 10 week.
Detailed Description
Fibromyalgia (FM) is a chronic and widespread pain condition, usually accompanied by several associated symptoms such as fatigue, sleep disorder, headache, irritable bowel syndrome and mood disorders. Recent studies point to the possibility of gluten protein having a role in the development of FM symptoms in a subgroup of patients. Fourteen patients with FM diagnosis will be kept on a diet restrict in gluten-free foods for a period 10 weeks. At the 7th week they received rice protein isolate capsules (placebo) for 7 days, followed by a 3-day wash-out and a new challenge with capsules containing 8 g/day of gluten (corresponding to 6,3g gluten protein) for another 7 days. In the initial period, at 8th week (final of placebo period) and after challenge with gluten (10th week), blood will be collected for analysis of inflammatory markers. Questionnaires will be carried out to evaluate the quantity and severity of FM symptoms and the impact of FM on daily routine. Inflammatory markers (IL-1bera, IL-6 and IL-10) will be evaluated in the blood. In the challenger period (gluten or placebo) questionnaires will be carried out to evaluate the quantity and severity of symptoms related to fibromyalgia and the impact of fibromyalgia on a daily basis. In addition, a questionnaire based on Salerno protocol was applied to evaluate the presence of NCGS.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Fibromyalgia
Keywords
Fibromyalgia; non-celiac gluten sensitivity
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Sequential Assignment
Model Description
All participants received placebo capsules and, after that, gluten capsules.
Masking
Participant
Allocation
Non-Randomized
Enrollment
26 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Gluten
Arm Type
Active Comparator
Arm Description
Capsules containing 8 g/day of gluten (6,3g of protein) were blindly administered for 7 days
Arm Title
Rice protein
Arm Type
Placebo Comparator
Arm Description
Capsules containing 6,4 g/day of rice protein were blindly administered for 7 days
Intervention Type
Dietary Supplement
Intervention Name(s)
Gluten
Intervention Type
Dietary Supplement
Intervention Name(s)
Rice protein
Primary Outcome Measure Information:
Title
Changes in fibromyalgia Symptoms by Salerno protocol
Description
Self report of symptoms intensity in the last week. Each item is scored 0 (no symptom) to 10 (very intense symptom).
Time Frame
Baseline, 4th and 8th weeks, 10th week
Secondary Outcome Measure Information:
Title
Changes in body weight
Description
measured in weight in kg
Time Frame
Baseline, 8th and 10th weeks
Title
Height
Description
measured in meters
Time Frame
baseline
Title
changes in BMI
Description
in kg of body weight/square of height
Time Frame
Baseline, 8th and 10th weeks
Title
Changes in IL-6 blood concentration
Description
measure by ELISA in ug/mL
Time Frame
Baseline, 8th and 10th weeks
Title
Changes in IL-10 blood concentration
Description
measure by ELISA in ug/mL
Time Frame
Baseline, 8th and 10th weeks
Title
Changes in IL-1beta blood concentration
Description
measure by ELISA in ug/mL
Time Frame
Baseline, 8th and 10th weeks
Title
changes in Food intake
Description
measured in % of kcal
Time Frame
Baseline, 8th and 10th weeks
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
• Women between 18 and 65 years of age with prior clinical diagnosis of FM, according to the American College of Rheumatology criteria of 2010
Exclusion Criteria:
Subjects diagnosed with positive serology for celiac disease or allergy to wheat
Subjects diagnosed with autoimmune diseases
Subjects with diseases that are not part of the comorbidities associated with FM and t hat could influence the results of the study
Pregnant or lactating women
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jacqueline I Alvarez-Leite, MD, PhD
Organizational Affiliation
Federal University of Minas Gerais
Official's Role
Principal Investigator
Facility Information:
Facility Name
Laboratório de Aterosclerose e Bioquimica Nutricional
City
Belo Horizonte
State/Province
Minas Gerais
ZIP/Postal Code
30161-970
Country
Brazil
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Impact of the Restriction of Sources of Gluten in Fibromyalgia Patients
We'll reach out to this number within 24 hrs